CoreCap Advisors’s Anavex Life Sciences AVXL Stock Holding History

CoreCap Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-660	Closed	-$5.66K	–	2800
2025 Q1	$5.66K	Buy	+660	New	+$6.23K	﹤0.01%	2051

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

CoreCap Advisors's AVXL Position: Q2 2025 in Review

CoreCap Advisors sold out of Anavex Life Sciences (AVXL) in Q2 2025, closing a stake of 660 shares — an estimated $5.66K sold.

CoreCap Advisors first reported a position in AVXL in Q1 2025 and held it in 1 quarter. The position peaked at $5.66K in Q1 2025. 178 funds tracked by Wall St. Rank hold AVXL as of Q2 2025.

CoreCap Advisors reported no remaining Anavex Life Sciences position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 660 Anavex Life Sciences shares in Q2 2025, an estimated $5.66K.
CoreCap Advisors first reported a position in Anavex Life Sciences in Q1 2025 and held it in 1 quarter.
CoreCap Advisors's Anavex Life Sciences position peaked at $5.66K in Q1 2025.
178 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.